RAD June 2024 Abstracts and Posters
687 Treatment of conjunctivitis in dupilumab-treated patients with atopic dermatitis: an observational study
Penny Asbell, Esen K. Akpek, Winston Chamberlain, Zhen Chen, Anna Coleman, Ana B. Rossi, Brad Shumel
688 The heterogeneous characteristics of itch vary by atopic dermatitis severity and differentially impact quality of life in children and adults: a prospective cohort study
Brandon Ansbro, BA; Jonathan I. Silverberg, MD, PhD, MPH
689 Unmet needs of managing atopic dermatitis: where do we stand in modifying vs. suppressing disease?
Sarah G. Brooks, BA, Lourdes M. Lopez, BS, Kayla D. Mashoudy, BS, Gil Yosipovitch, MD, PhD, Tali Czarnowicki, MD, MSc
690 SCORAD severity band threshold analysis from dupilumab clinical trials in adults with moderate-to-severe atopic dermatitis
Andreas Wollenberg, Eric L. Simpson, Yael A. Leshem, Alain Taieb, Norito Katoh, Jingdong Chao, Ana B. Rossi, Amy Praestgaard
691 Understanding patient and physician preferences when choosing between biologic and oral systemic treatment options for moderate-to-severe atopic dermatitis: a discrete choice experiment
Jorge Puelles, Pablo Arija, Nicholas Durno, Krystallia Pantiri, Ramkumar Subramanian, Katrin Jack, Olivier Chambenoit, Marco Boeri, Ben van Hout, Jonathan I. Silverberg
692 Dupilumab reduces atopic dermatitis lesion severity and extent in children eal-world registry
Lara Wine Lee, Alan D. Irvine, Michele Ramien, Danielle Marcoux, Eulalia Baselga, Marlies de Graaf, Martti Antila, Nelson A. Rosario Filho, Irene Lara-Corrales, Joel C. Joyce, Rajan Gupta, Patrick Redman, Annie Zhang
693 Efficacy and safety of orismilast, a potent PDE4B/D inhibitor, in adults with moderate-to-severe atopic dermatitis: a phase 2b randomized, double-blind, placebo-controlled clinical trial (ADESOS)
Jonathan Silverberg, Lawrence Eichenfield, Andrew Blauvelt, Alan D Irvine, Richard Langley, Emma Guttman, Richard Warren, Lars French, Claus Bang Pedersen, Anna Carlsson, Morten Lind Jensen, Morten O. A. Sommer, Kim Kjøller, Eric Simpson
694 Dupilumab improves itch and skin lesions in North American patients with prurigo nodularis: a subset analysis of the pooled results from two phase 3 trials (LIBERTY-PN PRIME and PRIME2)
Sarina B. Elmariah, Nicholas Mollanazar, H. Chi-ho Hong, Kirsten Walker, Daniel C. Butler, Amy Praestgaard, Joseph Zahn, Simmi Wiggins
695 Long-term dupilumab treatment is not associated with an increased overall risk of infections in adults with moderate-to-severe atopic dermatitis
Lisa A. Beck, Eric L. Simpson, Diamant Thaçi, Marjolein de Bruin-Weller, Mette Deleuran, Yoko Kataoka, Adam J. Friedman, Faisal A. Khokhar, Anna Coleman, Guy Gherardi, Zhen Chen, Elena Avetisova, Annie Zhang, Tien V. Nguyen
696 Sustained improvements over 140 weeks in signs, symptoms, and quality of life with upadacitinib in adolescents and adults with moderate-to-severe atopic dermatitis: integrated results from the phase 3 Measure Up 1 and Measure Up 2 studies
Vimal H. Prajapati, Christopher G Bunick, Kilian Eyerich, Linda Stein Gold, Fabrizio Galimberti, Brian Calimlim, Henrique Teixeira, Xiaofei Hu, Yang Yang, Cristina Sancho, Ayman Grada, Alan D Irvine